Please enable JavaScript to continue using this application.

Compare $ARCT vs $XFOR | Chartloom

Compare

$ARCT vs $XFOR

Arcturus Therapeutics Holdings Inc · X4 Pharmaceuticals Inc

ARCT

Arcturus Therapeutics Holdings Inc

XFOR

X4 Pharmaceuticals Inc

Compare $ARCT vs $XFOR

Comparing Arcturus Therapeutics Holdings Inc and X4 Pharmaceuticals Inc

ARCTArcturus Therapeutics Holdings Inc

XFORX4 Pharmaceuticals Inc

ARCTArcturus Therapeutics Holdings Inc

Market cap

$390M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.64x

Rev growth (TTM)

-76.0%

YTD performance

119.8%

52W performance

-35.2%

FCF yield

-18.7%

XFORX4 Pharmaceuticals Inc

Market cap

$274M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.09x

Rev growth (TTM)

-51.6%

YTD performance

-25.2%

52W performance

-12.3%

FCF yield

-32.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ARCT

XFOR

Detailed metrics comparison

ARCT

Arcturus Therapeutics Holdings Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

ARCT$390M

XFOR$274M

Enterprise Value

ARCT$199M

XFOR$156M

Price

ARCT$13.74

XFOR$2.91

P/E Ratio

ARCTN/A

XFORN/A

P/S Ratio

ARCT13.30x

XFOR17.32x

EV/Sales

ARCT6.78x

XFOR9.85x

EV/EBITDA

ARCT1.82x

XFOR0.00x

P/B Ratio

ARCT2.16x

XFOR1.81x

P/FCF Ratio

ARCTN/A

XFORN/A

EV/FCF

ARCT-2.73x

XFOR-1.76x

PEG Ratio

ARCTN/A

XFORN/A

Forward P/E (NTM)

ARCTN/A

XFORN/A

Forward P/S (NTM)

ARCT21.64x

XFOR28.09x

Revenue (TTM)

ARCT$29M

XFOR$16M

Revenue Growth (YoY)

ARCT-76.0%

XFOR-51.6%

Forward Rev Growth

ARCT107.7%

XFOR-27.7%

Gross Margin (TTM)

ARCT0.0%

XFOR81.5%

Operating Margin (TTM)

ARCT0.0%

XFOR0.0%

EBITDA Margin (TTM)

ARCT-339.0%

XFOR-544.2%

Net Margin (TTM)

ARCT-317.6%

XFOR-568.8%

FCF Margin (TTM)

ARCT-248.6%

XFOR-560.0%

Net Income (TTM)

ARCT$-93M

XFOR$-90M

FCF (TTM)

ARCT$-73M

XFOR$-89M

EPS (TTM)

ARCT-$3.28

XFOR-$0.71

ROE (TTM)

ARCT-4654.0%

XFOR-6305.0%

ROA (TTM)

ARCT-3646.0%

XFOR-3689.0%

ROIC (TTM)

ARCT-4654.0%

XFOR-4109.0%

Cash

ARCT$191M

XFOR$195M

Debt

ARCT$0

XFOR$77M

Net Cash/Debt

ARCT$191M

XFOR$118M

Current Ratio (TTM)

ARCT5.88x

XFOR11.30x

Quick Ratio (TTM)

ARCT5.76x

XFOR10.87x

Debt/Equity (TTM)

ARCT0.00x

XFOR0.49x

Debt/Assets (TTM)

ARCT0.0%

XFOR0.0%

Interest Coverage (TTM)

ARCTN/A

XFORN/A

Net Debt/EBITDA (TTM)

ARCT0.00x

XFOR0.00x

Beta

ARCT2.60

XFOR0.50

52W Performance

ARCT-35.2%

XFOR-12.3%

YTD Performance

ARCT119.8%

XFOR-25.2%

% from 52W High

ARCT-43.2%

XFOR-39.8%

% from 52W Low

ARCT149.8%

XFOR7.8%

Asset Turnover (TTM)

ARCT0.11x

XFOR0.06x

FCF Yield (TTM)

ARCT-18.7%

XFOR-32.3%

Earnings Yield (TTM)

ARCT-23.9%

XFOR-32.8%

Dividend Yield (TTM)

ARCTN/A

XFORN/A

Rule of 40

ARCT-324.5

XFOR-611.6

EV/GP/RG

ARCTN/A

XFORN/A

Ticker research

View ARCT research View XFOR research

Metric	ARCT Arcturus Therapeutics Holdings Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$390M	$274M
Enterprise Value	$199M	$156M
Price	$13.74	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	13.30x	17.32x
EV/Sales	6.78x	9.85x
EV/EBITDA	1.82x	0.00x
P/B Ratio	2.16x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.73x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.64x	28.09x
Revenue & Growth
Revenue (TTM)	$29M	$16M
Revenue Growth (YoY)	-76.0%	-51.6%
Forward Rev Growth	107.7%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-339.0%	-544.2%
Net Margin (TTM)	-317.6%	-568.8%
FCF Margin (TTM)	-248.6%	-560.0%
Net Income (TTM)	$-93M	$-90M
FCF (TTM)	$-73M	$-89M
EPS (TTM)	-$3.28	-$0.71
ROE (TTM)	-4654.0%	-6305.0%
ROA (TTM)	-3646.0%	-3689.0%
ROIC (TTM)	-4654.0%	-4109.0%
Financial Health
Cash	$191M	$195M
Debt	$0	$77M
Net Cash/Debt	$191M	$118M
Current Ratio (TTM)	5.88x	11.30x
Quick Ratio (TTM)	5.76x	10.87x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.50
52W Performance	-35.2%	-12.3%
YTD Performance	119.8%	-25.2%
% from 52W High	-43.2%	-39.8%
% from 52W Low	149.8%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.06x
FCF Yield (TTM)	-18.7%	-32.3%
Earnings Yield (TTM)	-23.9%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-324.5	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View ARCT research	View XFOR research

Valuation

P/S Ratio

ARCT

13.30x

XFOR

17.32x

EV/FCF

ARCT

-2.73x

XFOR

-1.76x

Growth & revenue

Revenue Growth TTM

XFOR

-51.6%

ARCT

-76.0%

Forward Revenue Growth

ARCT

107.7%

XFOR

-27.7%

Profitability & performance

Gross Margin

XFOR

81.5%

ARCT

0.0%

ROE

ARCT

-4654.0%

XFOR

-6305.0%

FCF Yield %

ARCT

-18.7%

XFOR

-32.3%

52-Week Performance

XFOR

-12.3%

ARCT

-35.2%

Detailed metrics comparison

ARCT

Arcturus Therapeutics Holdings Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

ARCT$390M

XFOR$274M

Enterprise Value

ARCT$199M

XFOR$156M

Price

ARCT$13.74

XFOR$2.91

P/E Ratio

ARCTN/A

XFORN/A

P/S Ratio

ARCT13.30x

XFOR17.32x

EV/Sales

ARCT6.78x

XFOR9.85x

EV/EBITDA

ARCT1.82x

XFOR0.00x

P/B Ratio

ARCT2.16x

XFOR1.81x

P/FCF Ratio

ARCTN/A

XFORN/A

EV/FCF

ARCT-2.73x

XFOR-1.76x

PEG Ratio

ARCTN/A

XFORN/A

Forward P/E (NTM)

ARCTN/A

XFORN/A

Forward P/S (NTM)

ARCT21.64x

XFOR28.09x

Revenue (TTM)

ARCT$29M

XFOR$16M

Revenue Growth (YoY)

ARCT-76.0%

XFOR-51.6%

Forward Rev Growth

ARCT107.7%

XFOR-27.7%

Gross Margin (TTM)

ARCT0.0%

XFOR81.5%

Operating Margin (TTM)

ARCT0.0%

XFOR0.0%

EBITDA Margin (TTM)

ARCT-339.0%

XFOR-544.2%

Net Margin (TTM)

ARCT-317.6%

XFOR-568.8%

FCF Margin (TTM)

ARCT-248.6%

XFOR-560.0%

Net Income (TTM)

ARCT$-93M

XFOR$-90M

FCF (TTM)

ARCT$-73M

XFOR$-89M

EPS (TTM)

ARCT-$3.28

XFOR-$0.71

ROE (TTM)

ARCT-4654.0%

XFOR-6305.0%

ROA (TTM)

ARCT-3646.0%

XFOR-3689.0%

ROIC (TTM)

ARCT-4654.0%

XFOR-4109.0%

Cash

ARCT$191M

XFOR$195M

Debt

ARCT$0

XFOR$77M

Net Cash/Debt

ARCT$191M

XFOR$118M

Current Ratio (TTM)

ARCT5.88x

XFOR11.30x

Quick Ratio (TTM)

ARCT5.76x

XFOR10.87x

Debt/Equity (TTM)

ARCT0.00x

XFOR0.49x

Debt/Assets (TTM)

ARCT0.0%

XFOR0.0%

Interest Coverage (TTM)

ARCTN/A

XFORN/A

Net Debt/EBITDA (TTM)

ARCT0.00x

XFOR0.00x

Beta

ARCT2.60

XFOR0.50

52W Performance

ARCT-35.2%

XFOR-12.3%

YTD Performance

ARCT119.8%

XFOR-25.2%

% from 52W High

ARCT-43.2%

XFOR-39.8%

% from 52W Low

ARCT149.8%

XFOR7.8%

Asset Turnover (TTM)

ARCT0.11x

XFOR0.06x

FCF Yield (TTM)

ARCT-18.7%

XFOR-32.3%

Earnings Yield (TTM)

ARCT-23.9%

XFOR-32.8%

Dividend Yield (TTM)

ARCTN/A

XFORN/A

Rule of 40

ARCT-324.5

XFOR-611.6

EV/GP/RG

ARCTN/A

XFORN/A

Ticker research

View ARCT research View XFOR research

Metric	ARCT Arcturus Therapeutics Holdings Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$390M	$274M
Enterprise Value	$199M	$156M
Price	$13.74	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	13.30x	17.32x
EV/Sales	6.78x	9.85x
EV/EBITDA	1.82x	0.00x
P/B Ratio	2.16x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.73x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.64x	28.09x
Revenue & Growth
Revenue (TTM)	$29M	$16M
Revenue Growth (YoY)	-76.0%	-51.6%
Forward Rev Growth	107.7%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-339.0%	-544.2%
Net Margin (TTM)	-317.6%	-568.8%
FCF Margin (TTM)	-248.6%	-560.0%
Net Income (TTM)	$-93M	$-90M
FCF (TTM)	$-73M	$-89M
EPS (TTM)	-$3.28	-$0.71
ROE (TTM)	-4654.0%	-6305.0%
ROA (TTM)	-3646.0%	-3689.0%
ROIC (TTM)	-4654.0%	-4109.0%
Financial Health
Cash	$191M	$195M
Debt	$0	$77M
Net Cash/Debt	$191M	$118M
Current Ratio (TTM)	5.88x	11.30x
Quick Ratio (TTM)	5.76x	10.87x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.50
52W Performance	-35.2%	-12.3%
YTD Performance	119.8%	-25.2%
% from 52W High	-43.2%	-39.8%
% from 52W Low	149.8%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.06x
FCF Yield (TTM)	-18.7%	-32.3%
Earnings Yield (TTM)	-23.9%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-324.5	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View ARCT research	View XFOR research